TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11442865
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C) received morphine sulphate 0.03 mg.kg‐1 at the end of surgery, caudally
Study: 11442865
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine or tramadol (presurgical)
Study: 11442865
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine (postsurgical)
Study: 34496
Drug: Flurazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam (30 mg)
Study: 2936352
Drug: Midazolam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (15 mg)
Study: 22623385
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) group with untreated mushrooms providing 0.85 μg/d ergocalciferol
Study: 22623385
Drug: M1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1 group with UV-treated mushrooms providing 8.8 μg/d ergocalciferol
Study: 22623385
Drug: M2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2 group with UV-treated mushrooms providing 17.1 μg/d ergocalciferol
Study: 11106838
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (specifically diuretics)
Study: 11106838
Drug: Hypertension (BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension (BP 160/95 or antihypertensive medication)
Study: 8797128
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg (increased to 40 mg after 8 weeks, average 25.6 mg)
Study: 8427433
Drug: MPC (meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPC (meperidine 2 mg/kg + promethazine 1 mg/kg + chlorpromazine)
Study: 8427433
Drug: MP (meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP (meperidine 2 mg/kg + promethazine 1 mg/kg)
Study: 3592208
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg ketamine intravenously
Study: 3592208
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine intravenously
Study: 12546253
Drug: Capitated Assertive
Normalized name: Lespedeza capitata flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capitated Assertive Community Treatment (ACT) program
Study: 10230169
Drug: Caffeinated soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated soft drink (CC)
Study: 9506802
Drug: Isotonic carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic carbohydrate‐electrolyte solution (CES)
Study: 19178101
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel applications (Test group B, n = 118)
Study: 1632174
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion and dextropropoxyfen per os
Study: 31675083
Drug: Incentive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive group (lottery-based incentive tied to daily self-weighing)
Study: 31675083
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly messages)
Study: 9927098
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide and albuterol sulfate
Study: 9927098
Drug: Albuterol base
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol base alone (control)
Study: 7485698
Drug: Ro 46‐2717
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 46‐2717 and Ro 46‐2924 vaccines (after third immunization)
Study: 7388852
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with lignocaine, procainamide, and practolol
Study: 31415378
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose, 1 μg/kg for 10 minutes and continuous infusion, 0.4 μg/kg/hr)
Study: 25854015
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Fluoxetine)
Study: 21454742
Drug: rhBMP-2/ACS (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP-2/ACS (1.5 mg/mL, total 12.0 mg)
Study: 16800837
Drug: Once-monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly ibandronate plus patient support programme (PSP)
Study: 16368038
Drug: Once-weekly alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly alendronate
Study: 15090625
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet (400 to 500 mg of dietary calcium/d supplemented with placebo)
Study: 9380804
Drug: Euclamin 20
Normalized name: Eucamint
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euclamin 20 mg + intermediate insulin (M3)
Study: 9380804
Drug: Euclamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euclamine 20 mg + intermediate insulin (M4)
Study: 28139568
Drug: Alternative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatments
Study: 21992869
Drug: Brief telephone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief telephone intervention plus treatment as usual
Study: 12832240
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/day)
Study: 17126974
Drug: Fluphenazine (6-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine (6-21 mg/day)
Study: 12015629
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (46 +/- 1 g) during the run (M+C)
Study: 12015629
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (M+C)
Study: 22203319
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg
Study: 8326053
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.6 mg/kg
Study: 7649958
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.9 mg/kg
Study: 2666335
Drug: Intravenous (I.V.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (I.V.) metronidazole
Study: 2666335
Drug: Intravenous (I.V.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (I.V.) metronidazole-gentamicin-ampicillin
Study: 812456
Drug: Immediate postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postoperative parenteral hyperalimentation
Study: 31806216
Drug: Warfarin triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin triple therapy
Study: 23395257
Drug: Alfacalcidol 0.25
Normalized name: alfacalcidol 0.25 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.25 μg twice daily
Study: 11880840
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine 20 microgram/kg
Study: 11880840
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine 10 microgram/kg
Study: 7604646
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d cetirizine
Study: 7604646
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d cetirizine
Study: 7604646
Drug: cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine (10 mg/d or 20 mg/d)
Study: 2672989
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% (1 ml/kg)
Study: 2672989
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% or 0.5% (Age (years +2)/10 ml per dermatome)
Study: 8999618
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 micrograms twice daily
Study: 2238755
Drug: Pancreatin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatin (6 x 2 capsules, 6 x 300 mg/d)
Study: 30224341
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma VEGF-A levels (>5.1 pg/mL)
Study: 27939574
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg capsule orally, 1 hour before surgery and 75 mg twice a day for 2 days postoperatively)
Study: 27939574
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 similar-looking multivitamin capsules)
Study: 21317170
Drug: teduglutide 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide 0.10 mg/kg/day
Study: 21317170
Drug: teduglutide 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide 0.05 mg/kg/day
Study: 21317170
Drug: teduglutide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: teduglutide (both doses)
Study: 18705947
Drug: High-dose human
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose human albumin (2 g/kg) administered in a 2-hour intravenous infusion within 5 hours of symptom onset
Study: 11451176
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment (daily dose of interferon) with ribavirin 1,000-1,200 mg
Study: 11451176
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (interferon thrice weekly) with ribavirin 1,000-1,200 mg
Study: 8152279
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) based treatment regimens
Study: 8152279
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy or IFN-monotherapy
Study: 27547925
Drug: Autologous fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fecal microbiota transplantation (FMT) administered by colonoscopy
Study: 11921013
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment for limited stage Hodgkin's lymphoma
Study: 389148
Drug: EMG feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG feedback therapy
Study: 27567897
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (IMT)
Study: 8824654
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg q.d.s.
Study: 12697594
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.1 mg
Study: 12697594
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.2 mg
Study: 30954338
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and topical tranexamic acid (TXA)
Study: 26616409
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (3 mg/kg/twice a day of zinc sulfate monohydrate orally for 10 days)
Study: 26616409
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic treatment without zinc (Control)
Study: 20522733
Drug: High-dose EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose EPO (30,000 IU/day for 3 days)
Study: 20522733
Drug: Low-dose EPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EPO (5,000 IU/week for 3 months)
Study: 18972289
Drug: MF‐DPI 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF‐DPI 400 microg QD PM (1 inhalation)
Study: 15906422
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (single oral dose)
Study: 3300241
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg/day)
Study: 31511031
Drug: Eutropin (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutropin (0.24 mg/kg/week, 6 times/week)
Study: 31511031
Drug: Comparator (Genotropin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (Genotropin, 0.24 mg/kg/week, 6 times/week)
Study: 26179482
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg
Study: 31606880
Drug: Ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 50 mg
Study: 19760932
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole) for 2 weeks
Study: 15813838
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy
Study: 15220014
Drug: Tigecycline 25
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 25 mg IV q12h for 7 to 14 days
Study: 15220014
Drug: Tigecycline 50
Normalized name: tigecycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline 50 mg IV q12h for 7 to 14 days
Study: 9692587
Drug: bupivacaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 1.5 mg/kg
Study: 9692587
Drug: bupivacaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 1.5 mg/kg with 1 in 200000 adrenaline
Study: 23428340
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose filtered back projection (FBP) with 120 kVp
Study: 23428340
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose filtered back projection (FBP) with 80 kVp
Study: 19772452
Drug: 6 U‐eq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 U‐eq plus two 2 U‐eq capsules (4.4 mg total)
Study: 19772452
Drug: two 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 10 U‐eq capsules (7.8 mg total)
Study: 9257203
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.7 mg/kg
Study: 9257203
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide 0.9 mg/kg
Study: 26076938
Drug: Colchicine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine, 1 mg daily (n=98)
Study: 21768314
Drug: 2 full
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 full doses (0.5 mL) of trivalent inactivated influenza vaccine (TIV)
Study: 21768314
Drug: 2 half
Normalized name: 1/2 Halfprin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 half doses (0.25 mL) of trivalent inactivated influenza vaccine (TIV)
Study: 19649267
Drug: Comparator drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator drugs (MAS3, artemether-lumefantrine, amodiaquine+sulfadoxine-pyrimethamine, artesunate+amodiaquine)
Study: 18029950
Drug: Intrathecal drug
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal drug delivery systems (IDDSs)
Study: 21526889
Drug: LRPT 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRPT 40 mg co-administered with clopidogrel 75 mg
Study: 21526889
Drug: LRPT 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRPT 40 mg co-administered with aspirin 81 mg
Study: 21526889
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg alone
Study: 10969672
Drug: Preoperative intraaortic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intraaortic balloon pump therapy
Study: 9080162
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II heparin-coated circuits
Study: 7504387
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate 2000 ml
Study: 7504387
Drug: 20 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml.kg-1 LMW-HES (Mw 120,000)
Study: 7504387
Drug: 20 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml.kg-1 HMW-HES (Mw 400,000)
Study: 3531957
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser photocoagulation treatment directed to the leakage site, using spot sizes of 200 mu in diameter, exposure times of 0.2 seconds, and low‐power intensities.
Study: 29318424
Drug: Pasireotide 60
Normalized name: pasireotide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 60 mg long-acting release
Study: 21553161
Drug: Regadenoson (400-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (400-μg bolus injection)
Study: 21553161
Drug: Adenosine (6-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (6-minute infusion)
Study: 12743984
Drug: gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m2 and vinorelbine 20 mg/m2 on days 1, 8, and 15 of each 28-day cycle
Study: 1356311
Drug: xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 200 mg two times a day
Study: 1356311
Drug: verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 240 mg once a day
Study: 2826563
Drug: Fiber (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber (15 g daily for 4 weeks)
Study: 29122620
Drug: Convective RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convective RF thermal therapy with Rezūm System
Study: 28404067
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infiltration with bupivacaine plus patient-controlled analgesia with morphine
Study: 16390890
Drug: DHEA (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100-400 mg/day)
Study: 12728743
Drug: Once-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of quetiapine (400 or 600 mg)
Study: 12728743
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of quetiapine (400 or 600 mg)
Study: 12728743
Drug: Once-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of quetiapine
Study: 12728743
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of quetiapine
Study: 9890410
Drug: Pure oxygen
Normalized name: Pure oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure oxygen administration for 30 min
Study: 9890410
Drug: Pure oxygen
Normalized name: Pure oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure oxygen administration for 30 min with right atrial pacing in 12 patients
Study: 2076623
Drug: Naproxen gel
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen gel (10%)
Study: 2076623
Drug: Flufenamic acid
Normalized name: Flufenamic acid
DrugBank: Flufenamic acid (DB02266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flufenamic acid gel (3%)
Study: 20146365
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin
Study: 18326958
Drug: Amlodipine/valsartan 10/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 10/160 mg
Study: 20236700
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg
Study: 16723303
Drug: HT50 (0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT50 (0.050 mg/day)
Study: 16723303
Drug: HT25 (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT25 (0.025 mg/day)
Study: 15523323
Drug: High-dose enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose enalapril
Study: 9024100
Drug: Micronized estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized estradiol, 0.5 mg
Study: 8328566
Drug: Sustained-release alprazolam
Normalized name: alprazolam Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release alprazolam (highest mean dose = 4.7 mg/day)
Study: 23530786
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg alone (Group P)
Study: 23530786
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg and remifentanil 1 µg/kg (Group R)
Study: 20610555
Drug: Morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 microg/kg
Study: 20610555
Drug: Morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 50 microg/kg
Study: 12720620
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation (200 ml sweet or salty sip feed twice daily, providing 500 kcal, 21 g protein per day)
Study: 12720620
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral supplementation)
Study: 9110065
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (500 mg six times a day)
Study: 9110065
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg three times a day)
Study: 9110065
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg per day)
Study: 12491207
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir
Study: 1901199
Drug: Rifater (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifater (combined formulation of isoniazid, rifampin, and pyrazinamide)